Emergency icon Important Updates
Department Cleveland Clinic Lou Ruvo Center for Brain Health
Primary Location CC Lou Ruvo Center for Brain Health
Type of Doctor Adults Only
Languages English
Surgeon No
Locations Specialties & Treatments

Treatment & Services

  • Neurology
View all 1 Treatment & Services +

Specialty in Diseases & Conditions

  • Acute Disseminated Encephalomyelitis (ADEM)
  • Devic's Disease
  • Multiple Sclerosis
  • Optic Neuritis
  • Transverse Myelitis
View all 5 Specialties +
Insurance

Insurance

Is Cleveland Clinic Nevada Part of Your Insurance?

For questions about accepted insurance plans for our Nevada locations and specific plan products including Medicare, please contact your insurance carrier directly.

View All Plans
Biography

About Carrie Hersh, DO

Carrie M. Hersh, DO, MSc, FAAN joined the faculty at Cleveland Clinic Lou Ruvo Center for Brain Health in August 2015 where she also serves as Associate Professor of Neurology at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. She also directs the Multiple Sclerosis (MS) Health and Wellness Program and the Professional Engagement Program and is Associate Program Director of the MS and Neuroimmunology Fellowship at the Cleveland Clinic Lou Ruvo Center for Brain Health. She completed a neuroimmunology fellowship at the Cleveland Clinic Mellen Center for MS Treatment and Research through a National MS Society Sylvia Lawry Award. She also earned a master’s degree in clinical research through the Clinical Research Scholars Program (CRSP) at Case Western Reserve University. She completed her adult neurology residency training at Cleveland Clinic and graduated medical school with honors from Nova Southeastern University-College of Osteopathic Medicine. She earned her BS degree in microbiology and neurobiology at University of Florida, graduating summa cum laude, and is a member of Phi Beta Kappa. She is a distinguished Fellow of the American Academy of Neurology (AAN) and graduated from the highly prestigious AAN Women Leading in Neurology Program in 2023.

A patient advocate and proponent of shared decision making, Dr. Hersh specializes in multiple sclerosis and related neuroimmunological disorders. She is particularly interested in real-world evidence, outcomes-based research and comparative effectiveness studies. She serves as PI of multiple investigator-initiated studies and clinical trials evaluating the effects of disease modifying therapies and wellness interventions on clinical, radiographic, and patient-reported outcomes. She is the lead investigator of the Multiple Sclerosis Partners Advancing Technology and Health Solutions program at Cleveland Clinic Lou Ruvo Center for Brain Health and serves on the study steering committee for the PCORI-funded DELIVER-MS clinical trial.

Dr. Hersh is a frequent lecturer on multiple sclerosis and related disorders topics at national and international meetings and has a prolific publication record, including peer-reviewed scientific journal articles, invited reviews, editorials, abstracts, and book chapters. She is the Editor of the Multiple Sclerosis issue of Neurologic Clinics (February 2024). She has special interest in gender equity, professional engagement, and burnout prevention among healthcare professionals, for which she has directed multiple national workshops and programs and is published on this topic. She is also an Advanced Peer Coach through the Cleveland Clinic Center of Excellence in Coaching and Mentoring. 

Dr. Hersh is a leader in the MS community in serving as Chair of the Healthcare Advisory Council for the Multiple Sclerosis Association of America, was the former Chair of the National MS Society’s regional Healthcare Provider Council, sits on the Board of Governors of the Consortium of MS Centers as Co-Chair of the Scientific Program Committee, and serves on numerous national and international steering committees, expert panels, and advisory boards. 

Education & Professional Highlights

Education & Professional Highlights

Appointed
2015

Education & Fellowships

Graduate School - Case Western Reserve University School of Medicine
Clinical Research
Cleveland, OH
2016

Fellowship - Cleveland Clinic
Neuroimmunology
Cleveland, OH
2015

Residency - Cleveland Clinic
Neurology
Cleveland, OH
2013

Internship - Cleveland Clinic
Internal Medicine
Cleveland, OH
2010

Medical Education - Nova Southeastern University
Davie, FL
2009

Undergraduate - University of Florida
Gainesville, FL
2005

Additional Training


Professional Highlights

  • Peer Reviewed Publications:

    Hersh, CM. The effects of environmental challenges on nociception/orphanin FQ-induced anxiety. J Undergrad Res. 2005; 6(7). http://ufdc.ufl.edu/UF00091523/00330/1j.
  • Hersh, C, Rae-Grant, A. Extended-release dalfampridine in the management of MS-related walking impairment. Ther Adv Neurol Disord. 2012; 5(4):199-204. doi: 10.1177/1756285612447091. PMID: 22783369.
  • Hersh, CM, Cohen, JA. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Immunotherapy. 2014; 6(3): 249-259. doi: 10.2217/imt.14.7. PMID: 24762071.
  • Hersh, CM, Hara-Cleaver, C, Rudick, RA, Cohen, JA, Bermel, RA, Ontaneda, D. Experience with fingolimod in clinical practice. Int J Neurosci. 2015; 125(9):678-85. doi: 10.3109/00207454.2014.969839. PMID: 25271798.
  • Hersh, CM, Love, TE, Cohn, S, Hara-Cleaver, C, Bermel, RA, Fox, RJ, Cohen, JA, Ontaneda, D. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Mult Scler Relat Disord. 2016 Nov; 10:44-52. doi: 10.1016/j.msard.2016.08.002. PMID: 27919497.
  • Hersh, CM, John, S, Subei, A, Willis, MA, Kosmorsky, G, Prayson, RA, Bhimraj, A. Optic neuropathy and stroke secondary to invasive Aspergillus in an immunocompetent patient. J Neuroophthalmol. 2016 Dec; 36(4):404-407. doi: 10.1097/WNO.0000000000000361. PMID: 27031126.
  • Hersh, CM, Love, TE, Bandyopadhyay, A, Cohn, S, Hara-Cleaver, C, Bermel, RA, Fox, RJ, Cohen, JA, Ontaneda, D. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Mult Scler J Exp Transl Clin. 2017 Aug; 3(3):2055217317715485. doi: 10.1177/2055217317715485. PMID: 28890796.
  • Moss, B, Rensel, MR, Hersh, CM. Wellness and the role of comorbidities in multiple sclerosis. Neurotherapeutics. 2017 Oct; 14(4):999-1017. doi: 10.1007/s13311-017-0563-6. PMID: 28785958.
  • Vollmer, B, Ontaneda D, Bandyopadhyay, A, Cohn, S, Nair, K, Sillau, S, Bermel, R, Corboy, J, Fox, RJ, Vollmer, T, Cohen, JA, Alvarez, A, Hersh, CM. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in two centers. Neurol Clin Pract. 2018 Aug; 8(4):292-301. doi: 10.1212/CPJ.0000000000000487. PMID: 30140580.
  • Hua, LH, Hersh, CM, Morten, P, Kusel, J, Lin, F, Cave, J, Varga, S, Herrera, V, Ko, J. The impact of price reductions after loss of exclusivity in a cost-effective analysis: fingolimod versus intramuscularly-administered interferon beta-1a for the treatment of relapsing forms of multiple sclerosis. J Manag Care Spec Pharm. 2019 Apr; 25(4):490-498. doi: 10.18553/jmcp.2019.25.4.490. PMID: 30917079.
  • Vollmer, B, Ontaneda, D, Harris, H, Nair, K, Bermel, R, Corboy, J, Fox, RJ, Vollmer, T, Cohen, JA, Alvarez, A, Hersh, CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Dec 15; 407:116498. doi:10.1016/j.jns.2019.116498. PMID: 31644992.
  • Conway, DS, Hersh, CM, Harris, HC, Hua, LH. Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population. Mult Scler J Exp Transl Clin. 2020 Jan 27; 6(1): 2055217320902488. doi: 10.1177/2055217320902488. PMID: 32064117.
  • Hua, LH, Harris, H, Conway, D, Hersh, CM. Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapy. J Neurol. 2020 Aug;267(8):2214-2220. doi: 10.1007/s00415-020-09816-1. PMID: 32270292.
  • Ontaneda, D, Tallantyre, EC, Raza, PC, Planchon, S, Nakamura, K, Miller, D, Hersh, C, Craner, M, Bale, C, Chaudhry, B, Gunzler, DD, Love, TE, Gerry, S, Coles, A, Cohen, JA, Evangelou, N. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemp Clin Trials. 2020 Aug;95:106009. doi: 10.1016/j.cct.2020.106009. PMID: 32320842.
  • Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups and Clinical Investigators: Hersh, C (I did not work closely with any of the listed authors on this publication). Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246.N Engl J Med. 2020. PMID: 32757523.
  • Mowry, E, Bermel, RA, Williams, JR, Benzinger, T, de Moor, C, Fisher, E, Hersh, CM, Hyland, MH, Izbudak, I, Jones, SE, Kieseier, BC, Kitzler HH, Krupp, L, Lui, YW, Montalban, X, Naismith, RT, Nicholas,, JA, Pellegrini, F, Rovira, A, Schulze, M, Tackenberg, B, Tintore, M, Tivarus, ME, Ziemssen, T, Rudick, RA. Harnessing real-world data to inform decision-making: multiple sclerosis partners advancing technology and health solutions (MS PATHS). Front Neurol. 2020 Aug 7;11:632. doi: 10.3389/fneur.2020.00632. PMID: 32849170.
  • Hersh, CM, Harris, H, Ayers, M, Conway, D. Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod. Mult Scler J Exp Transl Clin. 2020 Oct 13;6(4):2055217320959815. doi: 10.1177/2055217320959815. PMID: 33110616.
  • Hua, LH, Hersh, CM, Tian, F, Mowry, EM, Fitzgerald, KC. Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60. Mult Scler Relat Disord. 2020 Nov 23;47:102637. doi: 10.1016/j.msard.2020.102637. PMID: 33276238.
  • Hersh, CM, Harris, H, Conway, D, Hua, LH. Impact of switching from natalizumab to moderate versus high efficacy DMT in clinical practice. Neurol Clin Pract. 2020 Dec 10 (6) e53-e65; doi: 10.1212/CPJ.0000000000000809. PMID: 33510948. Received “Notable This Week” and “Most Read Article” designations.
  • Morrison-Banks, E, Michtich, K, Hersh, CM. How the COVID-19 pandemic has changed multiple sclerosis clinical practice: results of a nationwide provider survey. Mult Scler Relat Disord. 2021 Mar 18;51:102913. doi: 10.1016/j.msard.2021.102913. PMID: 33839482.
  • Hersh, CM, Brook, RA, Beren, IA, Rohrbacker, NJ, Lebson, L, Henke, C, Phillips, A. The implications of suboptimal treatment outcomes with disease-modifying drugs in employees with multiple sclerosis. J Med Econ. 2021 Mar 19;24:1:479-486.doi: 10.1080/13696998.2021.1906013. PMID: 33739915.
  • Hersh, CM, Kieseier, B, deMoor, C, Miller, D, Campagnolo, D, Williams, JR, Fitzgerald, K, Xiong, K, McGinley, M, Hyland, M, Ruddick, R, Ziemssen, T, Koulinska, I. Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: results of MS PATHS. 2021 Apr 15;7(2). doi: 10.1177/20552173211004634.
  • Ziemssen, T, Giovannoni, G, Alvarez, E, Bhan, V, Hersh, C, Hoffman, O, Oreja-Guevara, C, Robles-Cedeno, R, Trojano, M, Vermersch, P, Dobay, P, Khwaja, M, Stadler, B, Rauser, B, Hach, T, Piani-Meier, D, Burton, J. MSProDiscussTM, a useful digital tool to evaluate early signs of multiple sclerosis disease progression in a real world setting. J Med Internet Res. J Med Internet Res. 2021 Oct 6;23(10):e29558. doi: 10.2196/29558. PMID: 34612826.
  • Cohen, JA, Bermel, RA, Grossman, CI, Hersh, CM, Hyland, H, Mowry, EM, Naismith, R, Naylor, ML, Nicholas, J, Rajbhandari, R, Singh, CM, Tintorè, M, Zabalza, A, Ziemssen, T, Williams, JR, Montalban, X, on behalf of the MS PATHS Investigators. IgG Immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within MS PATHS. Mult Scler. 2022 Jan 7;13524585211061343. doi: 10.1177/13524585211061343. PMID: 34994577.
  • Hersh, CM, Altincatal, A, Kapadia, S, de Moor, C, Rudick, R, Williams, JR, Miller, C, Koulinska, I. Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics. Mult Scler J Exp Transl Clin. 2022 Jan 7;8(1):20552173211069852. doi: 10.1177/20552173211069852. PMID: 35024161.
  • Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial: Hersh, CM. Lancet Neurol. 2022 Apr 25:S1474-4422(22)00143-0. doi: 10.1016/S1474-4422(22)00143-0. Epub ahead of print. PMID: 35483387.
  • Conway DS, Briggs FB, Mowry EM, Fitzgerald KC, Hersh, CM. Racial disparities in hypertension management among multiple sclerosis patients. Mult Scler Relat Disord. 2022 Jun 15;64:103972. doi: 10.1016/j.msard.2022.103972. Epub ahead of print. PMID: 35728435.
  • Amin, M and Hersh, CM. Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener Dis Manag. 2022 Oct 31. doi: 10.2217/nmt-2021-0058. Epub ahead of print. PMID: 36314777.
  • Sotirchos, ES, Fitzgerald, KC, Singh, CM, Smith, MD, Reyes-Mantilla, M, Hersh, CM, Hyland, MH, Canissario, R, Simmons, S, Arrambide, G, Montalban, X, Comabella, M, Naismith, RT, Krupp, LB, Nicholas, JA, Ziemssen, T, Rudick, R, Fisher, E, Bermel, RA, Mowry, EM, Calabresi, PA. Associations of serum neurofilament light chain with clinical characteristics and radiological measures in a large real world MS population. Ann Clin Transl Neurol. 2022 Nov 25. doi: 10.1002/acn3.51704. Epub ahead of print. PMID: 36427295.
  • Sullivan, AB, Hersh, CM, Rensel, R, Benzil, D. Leadership inequity, burnout and lower engagement of women in medicine. J Health Serv Psychol. 2023. https://doi.org/10.1007/s42843-023-00078-9.
  • Hersh, CM, Morrow, SA, Williams, MJ, Amezcua, L, Halper, J, Wandersee, K. Diversity, Equity, and Inclusion in the Multiple Sclerosis Community: A Call to Action. Int J MS Care. 2023 May 23. https://doi.org/10.7224/1537-2073.2023-039.
  • Sotirchos, ES, Hu, C, Smith, MD, Lord, H, DuVal, A, Arrambide, G, Montalban, X, Akguen, K, Ziemssen, T,  Naismith, RT, Hersh, CM, Hyland, MH, Krupp, LB, Nicholas, JA, Bermel, RA, Mowry, EM, Calabresi, PA, Fitzgerald, KC. Agreement between reference resources for blood neurofilament light chain levels in people with multiple sclerosis. Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957. doi: 10.1212/WNL.0000000000207957. Epub ahead of print. PMID: 37816633.
  • Alvarez, E, Longbrake, EE, Rammohan, K, Stankiewicz, J, Hersh, CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023 Sep 15;79:105009. doi: 10.1016/j.msard.2023.105009. Epub ahead of print. PMID: 37783194.
  • Hersh, CM. Contemporary topics in multiple sclerosis. Neurol Clin. 2024 Feb;42(1):xiii-xv. doi: 10.1016/j.ncl.2023.08.001. Epub 2023 Aug 26. PMID: 37980125.
  • Aboseif, A, Roos, I, Krieger, S, Kalincik, T, Hersh, CM. Leveraging real world evidence and observational studies in treating multiple sclerosis. Neurol Clin. 2024 Feb;42(1):203-227. doi: 10.1016/j.ncl.2023.06.003. Epub 2023 Jul 21. PMID: 37980116.

Certifications

  • Psychiatry and Neurology - Neurology

Awards & Honors

  • 2001 University of Florida Honors Program
  • 2002 Phi Eta Sigma Honor Society, UF
  • 2002 National Society of Collegiate Scholars
  • 2002 Golden Key International Honor Society, UF
  • 2004 National Dean’s List
  • 2004 National Society of Collegiate Scholars Merit Award, UF
  • 2004 Presidential Recognition, UF
  • 2004 Chancellor’s List, UF
  • 2004 University Scholars Program, UF
  • 2004 Phi Kappa Phi Honor Society, UF
  • 2004 Phi Beta Kappa, UF
  • 2005-2009 Dean’s List, NSU
  • 2006 Sigma Sigma Phi Honor Society, NSU
  • 2009 Psi Sigma Alpha National Osteopathic Honor Society, NSU
  • 2012 7th Annual MASTER MS Fellowship Program
  • 2014 Consortium of MS Centers (CMSC) Scholarship Award
  • 2015 American Academy of Neurology (AAN) Fellows Scholarship Award
  • 2015 Neurological Institute Research Day Clinical Fellow Award, CCF
  • 2016 Travel Grant Award, European Committee for Treatment and Research in MS (ECTRIMS) 2016
  • 2016 Top Score Poster, ECTRIMS 2016
  • 2016 Top Score Poster, ECTRIMS 2016
  • 2016 Editor’s Choice for original research, Multiple Sclerosis and Related Disorders journal article “Comparative efficacy and discontinuation of dimethyl fumarate andfingolimod in clinical practice at 12-month follow-up”
  • 2017 Travel Grant Award, ECTRIMS 2017
  • 2018 Healthcare Headliner Award in Research/Science, Vegas Inc.
  • 2018 Top Score Poster, ECTRIMS 2018
  • 2019 Top Score Poster, ECTRIMS 2019
  • 2020 Fellow of the American Academy of Neurology (FAAN)

Innovations & Patents


Memberships

  • Consortium of Multiple Sclerosis Centers
  • National Multiple Sclerosis Society
  • Multiple Sclerosis Association of America
  • American Academy of Neurology
Research & Publications

Research & Publications

See publications for Carrie Hersh, DO.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Industry Relationships

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 7/24/2023, Dr. Hersh has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Hersh receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

  • Biogen Idec, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Patient Satisfaction Reviews

137 Patient Satisfaction Reviews

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Cleveland Clinic.

Overall Star Ratings
4.9 out of 5
Explains 4.9
Courtesy, Respect & Concern 4.9
Patient Rating of Doctor 4.9

39 Patient Comments

Reviewed on May 15, 2024

Dr Hersch was very thorough during my appt. I felt very comfortable with her.

Reviewed on May 10, 2024

Excellent doctor

Reviewed on May 1, 2024

Dr. Hersh is the most thorough, professional, yet warm and family like doctor I have ever seen.

Reviewed on Apr 23, 2024

Dr Hersh and the Cleveland Clinic staff are amazing and always make us feel like the most important people there.

Reviewed on Apr 10, 2024

I have recommended Carrie to other healthcare providers who could use her help. She is very professional kind and compassionate.

Reviewed on Mar 22, 2024

I love Dr. Hersch, she is outstanding and I feel very blessed to have her as my specialist.

Reviewed on Mar 19, 2024

I look up to and respect Carrie so much truly I feel so lucky for moving here for the soul fact that I got to know her! I know that above anything else my career is her upmost concern and she is absolutely brilliant. I feel so safe in her hands, and I feel so lucky to know her.

Reviewed on Mar 15, 2024

I love Dr Hearsh! She's the most wonderful person and really cares about me.

Reviewed on Mar 13, 2024

I absolutely love this facility. The staff is amazing. The doctors are amazing. I'm so blessed to have this clinic in Las Vegas.

Reviewed on Mar 13, 2024

I don't trust doctors never have until I met Dr. Carrie Hirsch. She is absolutely amazing. I trust her wholeheartedly. She is the reason why I have made big life decisions towards my health. The only doctor I trust with my MS care

Reviewed on Mar 1, 2024

The most difficult part of the process is making an appointment in a couple of months. One time I was told she was booked 4 or 5 months out. So had to schedule a video visit and that was about 2 months out. That Is just ludicrous to me. This last appointment was an exception. Usually for me to get an appoint promptly I would have to miss work so I can see the doctor as quickly aspossible. So, I'll just do what I have to get seen if an issue arises. I don't have to like though

Reviewed on Mar 1, 2024

I can not say enough good things about Dr Hersh. She listens, informs, and instructs with great a amount of thoughtfulness and care.

Reviewed on Feb 23, 2024

Dr. Hersh is extremely thorough and explains everything.

Reviewed on Feb 14, 2024

Dr. Hersh is top notch and genuine, she embodies what all providers should strive for. I thank God for her. I thank Cleveland Clinic for her.

Reviewed on Feb 13, 2024

Dr Carrie Hersch is always genuine and sweet. She pays full attention to your concerns and she has a very calming nature. She's amazing.

Reviewed on Feb 9, 2024

Dr Hersh is an excellent Doctor and always listens to what I have to say.

Reviewed on Feb 9, 2024

She has always been amazing.

Reviewed on Jan 26, 2024

Dr. Hersh is the best

Reviewed on Jan 23, 2024

Dr Hersh always gives me her undivided attention. She is absolutely amazing, and I am so thankful she is my doctor guiding me through this journey.

Reviewed on Jan 19, 2024

Talking to Dr. Hersh has created a positive outlook on my MS.She answers all my questions and relieves my worries with understanding what to expect.

Reviewed on Dec 27, 2023

Dr. Hersh was the most amazing doctor that I have ever encountered. As a fellow clinician, I can say that she is what al practitioners should strive to be.

Reviewed on Dec 15, 2023

Dr Hersh is phenomenal. So caring and top notch. She knows when to apply scientific expertise and when to apply layman terms. She matched my understanding perfectly.

Reviewed on Dec 15, 2023

I belive that Dr. Hersh and the Lou Ruvo team care for my well being

Reviewed on Dec 12, 2023

Great bedside manner absolutely a pleasure to work with. I gained more information from her than my previous doctor. Absolutely amazing.

Reviewed on Dec 5, 2023

Dr Hersch was AMAZING!! Not only friendly but a sweetheart first of all. She hugged me. Listened to my concerns. Guided me through the plan of care. She is doing everything to get me taken care of. I appreciate her so much!! She really cares for her patients

Reviewed on Nov 29, 2023

A great way to access the specialist with less stress and saves time. For non drivers it's essential! Dr is very compassionate and takes the time to work thru issues

Reviewed on Nov 14, 2023

Dr.hersh was awesome.

Reviewed on Oct 27, 2023

There is too much time spent by my provider on her typing skills as we talk. The lack of eye contact is very unprofessional. Another health care provider of mine also types everything that is done but he has a efficient medical assistant doing the typing so he can spend time during the visit. My provider uses that time instead of examining me, typing her office notes. Her time should be spent examining me instead of typing.

Reviewed on Oct 25, 2023

Dr. Hersh is the best

Reviewed on Oct 18, 2023

Dr. Hersh is amazing, she is thorough and answers my questions no matter how many times I ask her.

Reviewed on Sep 20, 2023

Dr. Hersh has a friendly compassionate convincing way of stating how the final outcome could be. With her supportive common sense approach, her suggestive disease modifying therapies become compelling.

Reviewed on Aug 30, 2023

Im so grateful to have Dr. Hersch as my doctor. Never had a doctor who really cares for her patients and listens to any concerns in every appointment.

Reviewed on Aug 23, 2023

Dr very professional and nice. Hoping she can provide some answers

Reviewed on Aug 9, 2023

This is the best care I've received in the entire valley. Thank you DR. Hersch and all the staff that is there. It has been a total positive experience!

Reviewed on Aug 2, 2023

Dr Hersh is the greatest doctor I've ever met. She truly cares about her patients. Idk where I'd be without her. I will forever be grateful.

Reviewed on Jun 27, 2023

Dr Carrie H was amazing, kind, very upbeat and positive.

Reviewed on Jun 23, 2023

Dr Hersh was extremely thorough in going over my recent MRI and lab results, she takes time to explain

Reviewed on Jun 23, 2023

Dr Hersh has a bedside manner second to none very caring

Reviewed on Jun 23, 2023

Dr Hersh and staff were caring and pleasant I'm incredibly happy to have found the right neurologist after bad experiences with the prior 3 this doctor and her team truly cares .

Back to Top